Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Weibin Hou

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
Small Science|April 11, 2025
Targeting PD-L1 with DNA Aptamers and Conjugated with Gemcitabine as a Novel Therapeutic Strategy for Bladder Cancer Chemotherapy Combined with ImmunotherapyXing Hu, Hongliang Zeng, Yongbo Peng, et al.
Cancer Science|December 28, 2021
Identification of an IDO1-based immune classifier for survival prediction of upper tract urothelial carcinomaWenlong Zhong, Meng Yang, Sida Cheng, et al.
Biomaterials Research|December 5, 2022
Targeting treatment of bladder cancer using PTK7 aptamer-gemcitabine conjugateWei Xiang, Yongbo Peng, Hongliang Zeng, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
Small Science|April 11, 2025
Targeting PD-L1 with DNA Aptamers and Conjugated with Gemcitabine as a Novel Therapeutic Strategy for Bladder Cancer Chemotherapy Combined with ImmunotherapyXing Hu, Hongliang Zeng, Yongbo Peng, et al.
Cancer Science|December 28, 2021
Identification of an IDO1-based immune classifier for survival prediction of upper tract urothelial carcinomaWenlong Zhong, Meng Yang, Sida Cheng, et al.
Biomaterials Research|December 5, 2022
Targeting treatment of bladder cancer using PTK7 aptamer-gemcitabine conjugateWei Xiang, Yongbo Peng, Hongliang Zeng, et al.
Pageof 4